2 days Pipeline Hackers Lose Access To Ransom Funds 2 days Military Coups Are Big Business 3 days Crypto Market Crashes As Tesla Turns Its Back On Bitcoin 4 days Gold Bulls Are Facing An Uphill Battle 5 days Has The Dogecoin Hype Fizzled? 7 days America s Semiconductor Shortage Is Just Getting Started 10 days The EU Begins Backtracking On China Trade 11 days Americans Are Sick Of Unfair Taxation 13 days No Jab, No Job: The New Hardline Policy of U.S. Employers 15 days What’s Included In Biden’s $6 Trillion Economic Plan? 16 days The “Great Car Comeback” Brightens Oil Demand Outlook 17 days The 3 Most Profitable Covid-19 Vaccine Stocks
Psychedelics Are Set To Explode In 2021
Published: May 17, 2021
Today, we re seeing the beginning of the next great biotech boom. and it has nothing to do with COVID-19.
Thanks to new laws sweeping the United States, there might be a groundbreaking new opportunity building for companies like Havn Life (
According to Reuters, mental health disorders is projected to be costing the world
$16 trillion in the 20 year period from 2010 to 2030.
And at the moment, we re left with hundreds of flawed solutions.
In fact, some are so harmful that less than 50% of patients that are prescribed these medications actually end up taking them.
/PRNewswire/ Today, the world seeing the beginning of the next great biotech boom. and it has nothing to do with COVID-19. Thanks to new laws sweeping the.
According to Reuters, mental health disorders is projected to be costing the world
$16 trillion in the 20 year period from 2010 to 2030.
And at the moment, we re left with hundreds of flawed solutions.
In fact, some are so harmful that less than 50% of patients that are prescribed these medications actually end up taking them.
That s the reason
big-time investors like PayPal co-founder Peter Thiel, Shark Tank star Kevin O Leary, and pot stock dynamo Bruce Linton are said to be investing money into the psychedelics space.
And they are not alone.
Even some of the biggest pharmaceutical companies like Johnson & Johnson and $195 billion giant Abbvie are